Sandu Pharmaceuticals
36.74
-0.11(-0.30%)
Market Cap₹35.49 Cr
PE Ratio22.89
IndustryHealthcare
Company Performance:
1D-0.30%
1M-5.11%
6M-24.47%
1Y-30.68%
5Y+20.86%
View Company Insightsright
More news about Sandu Pharmaceuticals
17Oct 25
Sandu Pharmaceuticals Seeks Shareholder Approval for Promoter Reclassification
Sandu Pharmaceuticals Limited has initiated a process to reclassify Akshath Finvest and Properties Private Limited from the promoter category to public category. The company is seeking shareholder approval through a postal ballot. Akshath Finvest currently holds 4,94,182 shares (5.12% of paid-up equity share capital). The Bombay Stock Exchange has granted approval for the reclassification, subject to shareholder consent. E-voting is scheduled from October 20, 2025, to November 18, 2025, with results expected by November 20, 2025. The reclassification aligns with SEBI's Listing Obligations and Disclosure Requirements Regulations.
 no imag found
14Oct 25
Sandu Pharmaceuticals Board Approves Postal Ballot for Promoter Reclassification
Sandu Pharmaceuticals Limited's Board of Directors has approved a postal ballot notice to seek shareholder approval for reclassifying M/s Akshath Finvest and Properties Private Limited from 'Promoter/Promoter Group' to 'Public' category. The e-voting process, with a cut-off date of October 15, 2025, will determine the outcome of this proposed change in the company's ownership structure.
 no imag found
15Aug 25
Sandu Pharmaceuticals Reports 33.8% Jump in Q1 Net Profit Despite Revenue Decline
Sandu Pharmaceuticals Limited reported mixed Q1 results with a 2.2% decrease in total income to ₹1,671.67 lakhs. However, net profit after tax increased by 33.8% to ₹22.33 lakhs, and earnings per share improved from ₹0.17 to ₹0.23. The company's operating profit margin was 3.17%, slightly lower than the previous quarter. The board approved these results on August 13.
 no imag found
13Aug 25
Sandu Pharmaceuticals Reports Q1 Profit, Declares Dividend, and Schedules 40th AGM
Sandu Pharmaceuticals reported Q1 revenue of Rs 1665.90 lakhs and profit after tax of Rs 22.33 lakhs. The Board declared a dividend of Rs 0.80 per share (8% of paid-up capital). The 40th AGM is scheduled for September 30 via video conferencing, with a book closure period from September 23-30. The company approved continuation of material related party transactions with Sandu Brothers Private Limited and the extension of CFO Shri Vijay Kajarekar's tenure beyond 70 years, both subject to shareholder approval.
 no imag found
16Jun 25
Sun Pharma's Halol Facility Faces FDA Scrutiny; Leadership Transition Announced
Sun Pharmaceuticals received eight FDA observations for its Halol facility, which is already under import alert. The company also announced a leadership transition, with Kirti Ganorkar set to become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi.
 no imag found
Sandu Pharmaceuticals
36.74
-0.11
(-0.30%)
1 Year Returns:-30.68%
Industry Peers
Sun Pharmaceutical
1,724.40
(+0.64%)
Divis Laboratories
6,291.00
(-0.10%)
Torrent Pharmaceuticals
4,241.70
(+0.36%)
Cipla
1,341.10
(+0.92%)
Dr Reddys Laboratories
1,280.40
(-0.15%)
Lupin
2,219.40
(-0.42%)
Zydus Life Science
900.75
(-0.18%)
Mankind Pharma
2,024.30
(-0.75%)
Aurobindo Pharma
1,158.80
(-1.08%)
Alkem Laboratories
5,392.00
(+0.28%)